 Lavanya Kondapalli
Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 10 | 2023 | 2097 | 1.880 |
Why?
| | Myocardial Infarction | 3 | 2023 | 927 | 1.100 |
Why?
| | Carcinoid Heart Disease | 1 | 2022 | 2 | 0.840 |
Why?
| | Pyridazines | 1 | 2020 | 46 | 0.680 |
Why?
| | Myocarditis | 1 | 2021 | 93 | 0.680 |
Why?
| | Cardiovascular Diseases | 5 | 2021 | 1727 | 0.660 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2020 | 95 | 0.660 |
Why?
| | Carotid Stenosis | 1 | 2020 | 79 | 0.650 |
Why?
| | Imidazoles | 1 | 2020 | 208 | 0.640 |
Why?
| | Protein Kinase Inhibitors | 2 | 2020 | 785 | 0.630 |
Why?
| | Immunotherapy | 2 | 2023 | 474 | 0.590 |
Why?
| | Atherosclerosis | 1 | 2020 | 341 | 0.560 |
Why?
| | Thrombosis | 1 | 2020 | 298 | 0.550 |
Why?
| | Triple Negative Breast Neoplasms | 3 | 2023 | 157 | 0.530 |
Why?
| | Anticoagulants | 1 | 2020 | 550 | 0.510 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 961 | 0.420 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 1879 | 0.410 |
Why?
| | Chorionic Gonadotropin | 1 | 2012 | 78 | 0.400 |
Why?
| | Fertilization in Vitro | 1 | 2012 | 71 | 0.390 |
Why?
| | Stroke | 1 | 2020 | 1022 | 0.380 |
Why?
| | Breast Neoplasms | 4 | 2023 | 1862 | 0.350 |
Why?
| | Cardiotoxicity | 2 | 2020 | 27 | 0.350 |
Why?
| | Medical Oncology | 2 | 2022 | 229 | 0.330 |
Why?
| | Estradiol | 1 | 2012 | 455 | 0.320 |
Why?
| | Lung Neoplasms | 1 | 2021 | 2177 | 0.310 |
Why?
| | Humans | 21 | 2023 | 114686 | 0.240 |
Why?
| | England | 1 | 2023 | 65 | 0.220 |
Why?
| | Anthracyclines | 4 | 2023 | 41 | 0.200 |
Why?
| | Morbidity | 1 | 2022 | 280 | 0.190 |
Why?
| | Heart Failure | 2 | 2023 | 1945 | 0.180 |
Why?
| | Biology | 1 | 2021 | 79 | 0.180 |
Why?
| | Molecular Targeted Therapy | 2 | 2020 | 347 | 0.180 |
Why?
| | Immune System | 1 | 2021 | 172 | 0.180 |
Why?
| | Catheter Ablation | 2 | 2014 | 288 | 0.170 |
Why?
| | Heart Diseases | 1 | 2023 | 331 | 0.170 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2020 | 61 | 0.170 |
Why?
| | Atrial Fibrillation | 2 | 2014 | 322 | 0.170 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2021 | 194 | 0.160 |
Why?
| | Drug Interactions | 1 | 2020 | 338 | 0.160 |
Why?
| | Immunologic Factors | 1 | 2020 | 220 | 0.160 |
Why?
| | Taxoids | 3 | 2023 | 93 | 0.150 |
Why?
| | Skin Neoplasms | 1 | 2005 | 756 | 0.150 |
Why?
| | Cardiology | 1 | 2020 | 259 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2023 | 332 | 0.140 |
Why?
| | United States | 6 | 2023 | 12183 | 0.140 |
Why?
| | Societies, Medical | 1 | 2020 | 664 | 0.140 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2015 | 16 | 0.130 |
Why?
| | Treatment Outcome | 4 | 2020 | 9088 | 0.130 |
Why?
| | Biomarkers, Tumor | 1 | 2021 | 1040 | 0.130 |
Why?
| | Aged | 7 | 2023 | 19074 | 0.120 |
Why?
| | Anesthesia, General | 1 | 2014 | 44 | 0.120 |
Why?
| | Pandemics | 1 | 2022 | 1317 | 0.110 |
Why?
| | Medicare | 3 | 2023 | 665 | 0.110 |
Why?
| | Risk Factors | 4 | 2020 | 8632 | 0.110 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 296 | 0.100 |
Why?
| | Birth Rate | 1 | 2012 | 19 | 0.100 |
Why?
| | Micromanipulation | 1 | 2012 | 12 | 0.100 |
Why?
| | Embryo Transfer | 1 | 2012 | 29 | 0.100 |
Why?
| | Nanoparticles | 1 | 2015 | 313 | 0.100 |
Why?
| | Cancer Survivors | 3 | 2021 | 205 | 0.100 |
Why?
| | Oocytes | 1 | 2012 | 170 | 0.090 |
Why?
| | Female | 9 | 2023 | 59507 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 1355 | 0.090 |
Why?
| | Pregnancy Outcome | 1 | 2012 | 337 | 0.090 |
Why?
| | Inflammation | 1 | 2020 | 2480 | 0.080 |
Why?
| | Odds Ratio | 1 | 2012 | 953 | 0.080 |
Why?
| | Forecasting | 1 | 2005 | 330 | 0.060 |
Why?
| | Electrophysiologic Techniques, Cardiac | 2 | 2014 | 70 | 0.050 |
Why?
| | Protein Kinases | 1 | 2005 | 307 | 0.050 |
Why?
| | Cohort Studies | 1 | 2012 | 4895 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 1 | 2023 | 184 | 0.050 |
Why?
| | Arrhythmias, Cardiac | 1 | 2023 | 279 | 0.050 |
Why?
| | Clinical Trials as Topic | 1 | 2005 | 932 | 0.050 |
Why?
| | Pregnancy | 1 | 2012 | 5518 | 0.040 |
Why?
| | American Heart Association | 1 | 2021 | 264 | 0.040 |
Why?
| | Cardiotonic Agents | 1 | 2020 | 119 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 811 | 0.040 |
Why?
| | Melanoma | 1 | 2005 | 620 | 0.040 |
Why?
| | Middle Aged | 3 | 2014 | 26737 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 316 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1167 | 0.040 |
Why?
| | Disease Management | 1 | 2020 | 560 | 0.030 |
Why?
| | Dibenzocycloheptenes | 1 | 2015 | 2 | 0.030 |
Why?
| | Comorbidity | 1 | 2020 | 1448 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2012 | 12550 | 0.030 |
Why?
| | Biological Availability | 1 | 2015 | 119 | 0.030 |
Why?
| | Administration, Cutaneous | 1 | 2015 | 117 | 0.030 |
Why?
| | Drug Compounding | 1 | 2015 | 89 | 0.030 |
Why?
| | Solubility | 1 | 2015 | 223 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2015 | 368 | 0.030 |
Why?
| | Philadelphia | 1 | 2014 | 46 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2015 | 511 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2015 | 470 | 0.030 |
Why?
| | Conscious Sedation | 1 | 2014 | 78 | 0.030 |
Why?
| | Adrenergic beta-Agonists | 1 | 2014 | 126 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1395 | 0.030 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2012 | 106 | 0.020 |
Why?
| | Decision Making | 1 | 2018 | 782 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2012 | 493 | 0.020 |
Why?
| | Adult | 1 | 2012 | 30550 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 2968 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 2894 | 0.020 |
Why?
| | Smoking | 1 | 2018 | 1383 | 0.020 |
Why?
| | Reoperation | 1 | 2012 | 514 | 0.020 |
Why?
| | Recurrence | 1 | 2012 | 935 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 1796 | 0.020 |
Why?
| | Incidence | 1 | 2014 | 2313 | 0.020 |
Why?
| | Rats | 1 | 2015 | 4958 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 1841 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2014 | 3003 | 0.020 |
Why?
| | Animals | 2 | 2020 | 31706 | 0.020 |
Why?
| | Obesity | 1 | 2018 | 2508 | 0.020 |
Why?
| | Male | 3 | 2015 | 55596 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2012 | 4411 | 0.010 |
Why?
| | Prospective Studies | 1 | 2014 | 6220 | 0.010 |
Why?
|
|
Kondapalli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|